Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by yorgosGKon May 01, 2018 2:39pm

111 Views

Post# 27965867

RE:RE:Hi..

Theyve covered. They already bought the shares. It was a special private placement. How do you think the shares out changed. That means they covered. The short sell data is all Echellon (granted, mixed with a few public shorts), but the dilution cancels out the covering. I know we all want to say there is 22M+ in short volume coming to cover but thats not how this works.

We have great support at these levels, top up. Also - Echellon is now a shareholder, they will give us exposure soon. The next PP will be made higher so we don't see this again.

Bullboard Posts

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi